Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Manisha Shah
Ohio State University Comprehensive Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Medstar Georgetown University Hospital
Washington D.C., District of Columbia, United States
- Mayo Clinic in Florida
Jacksonville, Florida, United States
- University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
- Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
- Mayo Clinic
Rochester, Minnesota, United States
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
- M D Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 8 May 2013
- Primary completion
- 13 Jul 2015
- Completion
- 9 Oct 2017
- Last update posted
- 3 Apr 2018
- Registered enrollment
- 25
- Registry id
- NCT01811212
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.